However, HR+/ Her2- breast cancer has been reported to be associated with a risk of relapse or recurrence, highlighting the need for individualized treatment protocols and the determination of the optimal duration of adjuvant treatment [30, 31]. The gene discussed is ERBB2; the disease is breast carcinoma.